Illumina and the State of the Genomics Market

Despite a drop in Illumina’s stock value over 2023-2024, its size, cash flow, leadership in the genomics industry, comprehensive services, and 90% market share in clinical genomics testing means it is poised to maintain its dominance in next-gen sequencing over the next 5 to 10 years. Emerging competition is also leading to further innovation within the company.